Abstract
IntroductionBreast adenoma is common. However, in the setting of post-transplantation immune suppression it may be expressed differently.Case presentationA 35-year-old Sudanese woman, with a history of renal transplantation two and half years prior to presentation, was on a single immune suppression therapy in the form of cyclosporine-A since the transplantation. During a regular follow-up visit, she was noticed to have gingival hypertrophy and bilateral breast and axillary swellings. She underwent successful surgical resection of the bilateral fibroadenomas.ConclusionsCyclosporine-A therapy post renal transplantation is associated with an increased incidence of benign breast changes as fibroadenoma. Regular follow-up and appropriate selection of immunosuppressant therapy are essential in the post transplantation management of these patients.
Highlights
Cyclosporine-A therapy post renal transplantation is associated with an increased incidence of benign breast changes as fibroadenoma
We present the case of a woman with bilateral breast fibroadenoma secondary to cyclosporineA therapy post renal transplantation
Cyclosporine-A therapy is associated with breast fibroblast proliferation and breast fibroadenoma
Summary
Cyclosporine-A therapy is associated with breast fibroblast proliferation and breast fibroadenoma. Awareness of the association between cyclosporine-A and fibroadenomas should help to achieve the correct diagnosis in patients post transplantation without subjecting them to unnecessary procedures. Authors’ contributions AD was involved in the diagnosis and management of the patient. AON was involved in data collection and writing of the manuscript. LAEH was involved in the tissue diagnosis and literature search necessary for this manuscript. AHF is the senior surgeon supervised diagnosis, management and writing of this manuscript. All authors have read and approved the final manuscript. Author details 1P.O. Box 102, Department of Surgery, Faculty of Medicine, University of Khartoum, Sudan.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
